Selective targeting of KRAS-driven lung tumorigenesis via unresolved ER stress
Iwao Shimomura, Naoaki Watanabe, Tomofumi Yamamoto, Minami Kumazaki, Yuji Tada, Koichiro Tatsumi, Takahiro Ochiya, Yusuke Yamamoto
Iwao Shimomura, Naoaki Watanabe, Tomofumi Yamamoto, Minami Kumazaki, Yuji Tada, Koichiro Tatsumi, Takahiro Ochiya, Yusuke Yamamoto
View: Text | PDF
Research Article Cell biology Oncology

Selective targeting of KRAS-driven lung tumorigenesis via unresolved ER stress

Abstract

Lung cancer with oncogenic KRAS makes up a significant proportion of lung cancers and is accompanied by a poor prognosis. Recent advances in understanding the molecular pathogenesis of lung cancer with oncogenic KRAS have enabled the development of drugs, yet mutated KRAS remains undruggable. We performed small-molecule library screening and identified verteporfin, a yes-associated protein 1 (YAP1) inhibitor; verteporfin treatment markedly reduced cell viability in KRAS-mutant lung cancer cells in vitro and suppressed KRAS-driven lung tumorigenesis in vivo. Comparative functional analysis of verteporfin treatment and YAP1 knockdown with siRNA revealed that the cytotoxic effect of verteporfin was at least partially independent of YAP1 inhibition. A whole-transcriptome approach revealed the distinct expression profiles in KRAS-mutant lung cancer cells between verteporfin treatment and YAP1 knockdown and identified the selective involvement of the ER stress pathway in the effects of verteporfin treatment in KRAS-mutant lung cancer, leading to apoptotic cell death. These data provide novel insight to uncover vulnerabilities in KRAS-driven lung tumorigenesis.

Authors

Iwao Shimomura, Naoaki Watanabe, Tomofumi Yamamoto, Minami Kumazaki, Yuji Tada, Koichiro Tatsumi, Takahiro Ochiya, Yusuke Yamamoto

×

Figure 4

A whole-transcriptome analysis in KRAS-mutant lung cancer cells between verteporfin treatment and YAP1 knockdown.

Options: View larger image (or click on image) Download as PowerPoint
A whole-transcriptome analysis in KRAS-mutant lung cancer cells between ...
(A) Principal component analysis (PCA) of A-549 cells treated with YAP1 siRNA and verteporfin at various concentrations. (B) Heatmap showing the upregulated and downregulated genes following treatment with YAP1 siRNAs and verteporfin at various concentrations. (C) GSEA of the A-549 cells treated with verteporfin at various concentrations. NES, normalized enrichment score. The P values in the graphs were calculated by GSEA. (D) GSEA of the A-549 cells treated with YAP1 siRNAs. The P values in the graphs were calculated by GSEA. (E) Normalized enrichment scores from GSEA of all hallmark gene sets by following verteporfin treatment. EMT, epithelial-mesenchymal transition. (F) Normalized enrichment scores from GSEA of all hallmark gene sets by YAP1-knockdown experiments.